Featured Research

from universities, journals, and other organizations

Potential New Antibody Treatment For Autoimmune Diseases

Date:
January 24, 2009
Source:
University of California - San Francisco
Summary:
Scientists have discovered an abnormality in a patient's immune system that may lead to safer therapies for autoimmune diseases such as rheumatoid arthritis and colitis, as well as potential new ways to treat transplant rejection.

Scientists at UCSF have discovered an abnormality in a patient’s immune system that may lead to safer therapies for autoimmune diseases such as rheumatoid arthritis and colitis, as well as potential new ways to treat transplant rejection.

The research identified antibodies from a woman’s immune system that prevent infection-fighting T cells from moving through her blood stream and entering her body’s organs to attack invaders such as bacteria or viruses. Findings appear in the current online edition of “The FASEB Journal,” the official journal of the Federation of American Societies for Experimental Biology.

Based on studies in which the woman’s antibodies were transferred into mice, researchers hope these antibodies can be used to treat patients with autoimmunity or transplant recipients whose immune systems attack a transplanted organ or tissue.

Autoimmunity occurs when the body perceives its own cells or tissue as foreign organisms and creates an immune response to itself. Autoimmune diseases affect approximately five to eight percent of Americans and their prevalence is increasing, according to the National Institute of Allergy and Infectious Diseases. The majority of people with autoimmune diseases are women.

“This is the first selective antibody of its type discovered in a patient,” said lead study author Edward J. Goetzl, MD, UCSF professor of medicine and immunology. “Antibodies that react more generally against blood cells, such as T cells, previously have been identified. However, this is the first to block a specific aspect of T-cell function. Our study offers a potential new approach to developing safer, more targeted therapies based on human antibodies.”

Therapies using proper doses of these newly discovered antibodies may carry less risk of infections or tumors than current treatments, since the antibodies target T cells’ specific patrolling activities, rather than their overall function.

Goetzl’s team evaluated a woman with a low number of blood T cells and frequent infections in the ears, urinary tract and lungs. The infection of several organs suggested a defect in the patient’s immune system similar to Acquired Immune Deficiency Syndrome (AIDS), but the patient tested negative for human immunodeficiency virus (HIV).

Further studies revealed that the patient’s CD4 T cells did not move out of her lymph nodes as they would in a normal immune system because her body created antibodies to one type of sphingosine 1-phosphate (S1P) receptor. S1P is critical to appropriate immune responses since it regulates T- and B-cell movement throughout the body by interacting with its receptor. The patient’s antibodies blocked the signaling that triggers T-cell movement from the thymus and lymph nodes into blood and then into many organs.

Researchers then explored whether the woman’s antibodies effectively could inhibit an autoimmune response in mice. Antibodies against the S1P receptor, created from the patient’s antibody-producing cells, were injected into mice that were induced to develop colitis. The result was a significant reduction in severity of their diseases, including colitis-associated weight loss, in those mice compared to mice that did not receive the antibodies.

“These results have broad biological implications, since the cells that carry out our immune responses are present in every organ,” said Goetzl, director of UCSF Allergy and Immunology Research, which focuses on developing new diagnostic approaches and treatments for allergic and immunological diseases.

Funds from UCSF, the National Institutes of Health and the Rainin Post-Doctoral Training Fund, an independent foundation, supported this research.

Co-authors of the study are Jia-Jun Liao, Mei-Chuan Huang, Katharine Fast, Katherine Gundling, and Mahesh Yadav, all from the UCSF Department of Medicine; Matthias R. Wabl of the UCSF Department of Microbiology-Immunology; and James R. Van Brocklyn of the Ohio State University Department of Pathology.


Story Source:

The above story is based on materials provided by University of California - San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Francisco. "Potential New Antibody Treatment For Autoimmune Diseases." ScienceDaily. ScienceDaily, 24 January 2009. <www.sciencedaily.com/releases/2009/01/090122100836.htm>.
University of California - San Francisco. (2009, January 24). Potential New Antibody Treatment For Autoimmune Diseases. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2009/01/090122100836.htm
University of California - San Francisco. "Potential New Antibody Treatment For Autoimmune Diseases." ScienceDaily. www.sciencedaily.com/releases/2009/01/090122100836.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins